http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0903057-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40f3b913c455f6f285b9a1f90493e8ce |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 |
| filingDate | 2009-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_104a58cb272e8ed4788f29ba741c432f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_316a5b4fbd3fde84f5573df97b0c0389 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64bfcdecc9464dd96f506b090ad6aeb1 |
| publicationDate | 2010-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0903057-A2 |
| titleOfInvention | Clinical indication for herbal medicine extracted from artemisia artemisifolia, hatusima. for human infection with toxoplasma gondii |
| abstract | Clinical indication of herbal medicine extracted from Artemisia artemisifolia, Hatusima. for human infection with Toxoplasma gondii. Patent of Invention for the treatment of toxoplasmosis referring to a second use (clinical indication) of the artisanal originally Swiss medicine extracted from Artemisia anua, imported and distributed in the country under the tradename Plasmotrin <32>, used for malaria treatment. Its prescription in Brazil is restricted to endemic regions of the North and Northeast. The drugs used to treat toxoplasmosis have no action on the cyst and no indication for the chronic phase of infection, ie there is no treatment during the latent phase of the parasite. The treatment considered standard for toxoplasmosis is the combination of pyrimethamine and sulfonamides that act synergistically on the metabolism of phallic acid acting on the proliferative forms of Toxo plasma gondu. However, due to their toxicity, the therapeutic efficacy of this combination may be seriously limited, as these drugs cause significant side effects (Lescano et al, 2004). It is expected with the experimental and clinical trials of Artesu nato, extracted from Artemisia ai-temisifolia of Amazonian origin, the perception of the mechanism of action of the phytotherapic compound on bradyzoites and tachyzoites, latent and proliferative forms of the parasite that as the reference drug expects. Reduction of toxicity in immunosuppressed individuals or sensitivity to the medication administered and also in children and pregnant women after commercialization of the product. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108902968-A |
| priorityDate | 2009-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.